MASTER DATA & BIOLOGICAL SAMPLE TRANSFER AGREEMENT

This Master Agreement ("Agreement") is made effective as of April 17, 2020 (the "Effective Date") by and among the Participating Institutions.

This Agreement is intended to govern the exchange of data and/or biological samples that a Providing Party will provide to a Receiving Party for the purpose of conducting COVID19-related basic/clinical research activities (the "Research");

This Agreement is made in compliance with section 44(5) of the Personal Health Information Protection Act, 2004, S.O. 2004, c. 3 ("PHIPA").

The parties agree as follows:

1. **Definitions.** As used in this Agreement, the term:
   a) "Data" means all personal data (including without limitation medical data and information and other personal health information) and all other information which is provided by a Providing Party to a Receiving Party for the purpose of carrying out a Study and/or other Research Project;
   b) "Sample(s)" means human biological samples and materials derived from human subjects including, but not limited to, blood, excrement, saliva and tissue, and such other Research-related materials and reagents, which is provided by a Providing Party to a Receiving Party for the purpose of carrying out a Study and/or other Research Project;
   c) "Data/Sample(s)" means Data and/or Sample(s);
   d) "Implementing Form" means the form document executed from time to time between parties to memorialize the details of specific Samples and/or Data being transferred between such parties, in a form substantially similar to that of Schedule A;
   e) "Joinder Letter Agreement" means the letter agreement executed by a party after the Effective Date by which such party becomes a signatory to the Agreement, such letter agreement in a form substantially similar to that of Schedule B;
   f) "Participating Institutions" means the parties to this Agreement and the parties who execute a Joinder Letter Agreement, as may be listed (and periodically updated) on Schedule C;
   g) "Permitted Use" means the use consistent with the purpose of this Agreement in respect of the Research, as further documented in an Implementing Form;
   h) "Providing Party" means a party to this Agreement providing Samples and/or Data to a Receiving Party, as such is documented in an Implementing Form;
   i) "Providing Party Investigator" means the Providing Party investigator specified as such in an Implementing Form;
   j) "Receiving Party" means a party to this Agreement receiving Samples and/or Data from a Providing Party, as such is documented in an Implementing Form;
   k) "Receiving Party Investigator" means the Receiving Party investigator specified as such in an Implementing Form;
   l) "Research Project" means a project relating to the Research which is not a Study, and involves some or all of the Participating Institutions.
   m) "Study" means a study relating to the Research that has been approved by a REB and involves some or all of the Participating Institutions.

2. **Compliance.** In transferring the Data/Sample(s) the parties shall comply with all applicable laws, regulations, guidelines, policies and generally accepted standards for research practices ("Applicable Law"). The Providing Party will prepare and furnish the Data/Sample(s) in accordance with PHIPA including without limitation obtaining all appropriate consents. The Data/Sample(s) will not be collected and/or transferred until the Providing Party's research ethics board ("REB") and, if applicable the Receiving Party’s REB, have: a)
approved the Research protocol; and b) approved the Research informed consent forms or waived the requirement to obtain consent. If it is determined that REB approval is required for the Permitted Use, no Data/Sample(s) shall be transferred until the Receiving Party has provided a copy of such REB approval to the Providing Party. The Providing Party retains the right to refuse the transfer of any Data/Sample(s) until a copy of such REB approval has been received. The Providing Party retains the right but not the obligation to conduct audits of Receiving Party’s compliance with this Agreement upon reasonable advance written notice to Receiving Party and at mutually acceptable times. If there is a breach of the Agreement by Receiving Party, Providing Party may require that all Data/Sample(s) be returned promptly to Providing Party or destroyed in a secure manner at Providing Party’s option. The Providing Party retains the right, acting on reasonable grounds, to refuse the transfer of the Data/Sample(s) requested hereunder.

3. **Transfers.** Upon parties agreeing to a specific transfer of Data/Sample(s) pursuant to the terms of this Agreement, the particulars of the Data/Sample(s) to be transferred between such parties and the Permitted Use, and such other terms and provisions associated with the transfer as the parties may separately agree to, shall be set out in an Implementing Form, with each such Implementing Form to specifically reference and incorporate the terms of this Agreement. Notwithstanding, the parties may explicitly agree to amend or override any term or provision of this Agreement in an Implementing Form. The parties to an Implementing Form shall be solely responsible for the implementation, administration (including recordkeeping), supervision and performance of any Study and Research Project described therein, and for clarity shall be further solely responsible for maintaining adequate record(s) of all such executed Implementing Form(s).

4. **New Parties.** In the future, additional institution(s) may agree to be bound by the terms and provisions of this Agreement as evidenced by execution of a Joinder Letter Agreement in the form attached as Schedule B. Upon execution of said Joinder Letter Agreement, said institution shall be deemed to be a party to this Agreement as if it had been an original party hereto. On execution, copies of executed Joinder Letter Agreement(s) will be provided to the party providing administrative support for the purpose set out in Article 17.

5. **Use of Sample(s).** The parties acknowledge that the Sample(s) may contain one or more infectious agents and may have additional unknown and hazardous properties. Receiving Party shall use the Samples under appropriate containment conditions, in a safe and careful manner.

6. **Safeguards and Notification.** The Receiving Party shall use appropriate safeguards (including without limitation with respect to encrypting identifying numbers, linking files, storing and retrieving files from secured locations) to prevent any unauthorized use or disclosure of the Data/Sample(s) and shall promptly report to the Providing Party any unauthorized use or disclosure of which the Receiving Party becomes aware.

7. **Non-Disclosure of Data/Sample(s).** The Receiving Party shall limit access to the Data/Sample(s) only to its internal personnel and/or agents who need access for the purposes herein and who are bound by the same confidentiality obligations herein (“Research Staff”). Without limitation, the Receiving Party agrees that it/he/she shall, and shall require its/his/her Research Staff, to:
   a) maintain Data/Sample(s) in confidence, and not disclose Data/Sample(s) except as permitted by this Agreement (including any Implementing Form);
   b) use Data/Sample(s) solely for the Permitted Use, in compliance with:
      (i) as appropriate, the Study protocol as approved by the Providing Party’s and/or Receiving Party’s REB and as amended from time to time, provided that amendments are approved by the Providing Party’s and/or Receiving Party’s REB (the “Protocol”);
      (ii) any written conditions imposed by the Providing Party’s or Receiving Party’s REB;
      (iii) the Research subject’s consent consistent with the informed consent form approved by the Providing Party’s REB (the “Consent”) or, if the requirement to obtain consent has been waived, or otherwise determined to be unnecessary, by the Providing Party’s REB, the waiver of consent given by the Providing Party’s REB (the “Waiver”);
(iv) any other conditions or restrictions imposed by Providing Party relating to the use, security, disclosure, return or disposal of the Data/Sample(s) as set out in this Agreement (including any Implementing Form);

c) not use the Data/Sample(s) to re-identify any individuals;

d) not transfer the Data/Sample(s) to any third parties without the prior written consent of the Providing Party and without obligating such third parties to comply with the terms and conditions hereof, except as permitted in the Implementing Form. Notwithstanding the forgoing, the Receiving Party may transfer the Data/Sample(s):

(i) to regulatory authorities and health authorities, provided that the Receiving Party gives prior written notice of such intended disclosure to the Providing Party where possible;

(ii) as otherwise permitted by the Consent or Waiver; or

(iii) in order to comply with Applicable Law or judicial process, or with a court or regulatory order, provided that the Receiving Party gives prior written notice of such intended disclosure to the Providing Party and takes all lawful actions that are reasonable in the circumstances to minimize the extent of such disclosure and obtain confidential treatment for such disclosure;

e) securely destroy the Data/Sample(s) as required by the Protocol or instructed by the Providing Party and provide a written confirmation of the manner of destruction in a form acceptable to Providing Party.

8. **Contact with Subjects/Individuals.** The Receiving Party shall not make contact or attempt to make contact with an individual unless the Providing Party first obtains the individual’s consent to be contacted, except to the extent that the Receiving Party is otherwise the individual’s health information custodian.

9. **Confidential Information.** Receiving Party agrees that information concerning the Data/Sample(s) and all characteristics of the Data/Sample(s) known at the Effective Date of this Agreement (“Confidential Information”), shall be held in confidence by Receiving Party. Confidential Information excludes information which:

a) is or becomes known or available to the public through no breach of the Receiving Party’s obligations under this Agreement;

b) becomes known to the Receiving Party from a third party other than the Providing Party who has a lawful right to make such disclosure and is not in breach of any confidentiality obligation between such third party and the Providing Party; or

c) is required by law or court order to be disclosed, provided, however, that the Receiving Party provides the Providing Party with reasonable prior notice so that the Providing Party may seek a protective order or other appropriate remedy and discloses only the portion of the Confidential Information that the Receiving Party is legally required to disclose.

10. **Financial Matters.** Each party will bear its own costs of implementing this Agreement (and any Implementing Form hereunder).

11. **Intellectual Property.** Except as expressly provided herein, no right, title or interest in and to the Data/Sample(s) is granted to the Receiving Party or implied hereunder. The Receiving Party shall own the results arising out of the use of the Data/Sample(s) (the “Results”). The Providing Party shall have the right to use the Study or Research Project Results for non-commercial, academic, educational, clinical, and research purposes with the further right to grant sublicenses for similar purposes, as well as for Publications in accordance with this Agreement. It is recognized that the existing and/or already conceived inventions, discoveries and technologies of the Receiving Party and Providing Party are their separate property and are not affected by this Agreement. Intellectual property rights to any discoveries or inventions made in the course of any particular Study or Research Project and associated with a particular transfer of Data/Sample(s) (the “Project Intellectual Property”) will be jointly owned by the Receiving Party and Providing Party. Such parties
shall negotiate in good faith at a later date, an inter-institutional agreement to govern rights to transfer, license or assign the Project Intellectual Property to third parties, taking into account each of the party's contributions (including contribution of Sample(s), Data, and other intellectual and material contributions) to the Project Intellectual Property. Notwithstanding, the Receiving Party and Providing Party shall each retain a non-exclusive right to use Project Intellectual Property for their own internal clinical activities as well as internal non-commercial research and teaching purposes.

12. **Publication.** The Receiving Party and Providing Party shall have the right to use the Results as part of a publication or presentation of the results of the Research. The Receiving Party and Providing Party shall not include any personally identifying information in any publication or presentation. The contributions of the respective Providing Party Investigator and Receiving Party Investigator to the Research shall be acknowledged appropriately in any such publication or presentation in accordance with academic standards.

13. **Warranties/Liability.**
   a) **Disclaimer.** Any Data/Sample(s) provided or exchanged pursuant to this Agreement is understood to be experimental in nature and is provided "As Is". The Providing Parties do not make any representations nor extend any warranties or conditions of any kind, either expressed or implied, whatsoever in respect of the Data/Sample(s).
   
   b) Each party assumes all liability for damages which may arise from its own activities carried out in connection with the Research and any Project Intellectual Property. No party shall be liable to any other party to this Agreement for any loss, claim or demand made by a party to this Agreement, or made against a party to this Agreement by any other party, due to or arising from the conduct of the Research or any use of Project Intellectual Property, except to the extent permitted by law when caused by gross negligence or wilful misconduct, or otherwise arising from material breach of this Agreement. Except as otherwise provided herein, no party shall be responsible for any lost profits, lost opportunities, or other indirect or consequential damages suffered by another party as a result of the conduct of the Research or the performance of this Agreement.

14. **Term/Termination.**
   a) This Agreement shall commence on the Effective Date and shall terminate on December 31, 2021 or until the last Study or other Research Project further to an Implementing Form under this Agreement has concluded or closed, whichever is earlier. Notwithstanding and for clarity, all Implementing Form(s) that are stated to survive or which by their nature are intended to survive, shall survive the expiration or earlier termination of this Agreement.
   
   b) Each Research Project and Study will commence and terminate in accordance with the terms of the corresponding Implementing Form. Notwithstanding the aforementioned, a Study will not commence at the site of a Participating Institution, as a Providing and/or Receiving Party as the case may be, until that Participating Institution's REB, or a centralized REB of record, has approved the Study.

15. **Dispute Resolution.** In the event of any dispute arising in connection with this Agreement, the relevant parties agree to use good faith efforts to amicably resolve the dispute as between such parties.

16. **Schedules.** The following Schedules are attached to the Agreement:
   
   Schedule A: Form of "Implementing Form"
   Schedule B: Form of "Joinder Letter Agreement"
   Schedule C: Participating Party List (as updated)

17. **Administrative Matters.** It is the intention of the parties to designate a party to initially provide administrative support to maintain an updated list of all Participating Institutions. Excepting a Study or
Research Project on which it is a participant, such party providing administrative support shall **not** be responsible for the implementation, administration (including recordkeeping), supervision or performance of any Study or Research Project (and any Implementing Form(s) associated therewith).

18. **Insurance.** During the Term of this Agreement, and for the duration of its obligations surviving expiration or termination of this Agreement, each party shall maintain sufficient insurance to cover its liabilities in respect of its performance under this Agreement (and any associated Implementing Form(s)).

19. **General Terms and Conditions.** (a) No party shall be entitled to assign or transfer this Agreement or the rights and obligations hereunder to any third party without the prior written approval of the other parties. (b) This Agreement and the Implementing Form(s) associated with a particular Data/Sample(s) transfer represent the entire understanding between or among the parties related to such Data/Sample(s) transfer, and supersedes all previously or contemporaneously executed agreement(s) related to the transfer of such particular Data/Sample(s) between or among the parties. Notwithstanding the above, this entire Agreement is not intended to, nor shall it, conflict or supersede any existing or future agreements between a Participating Institution and Sinai Health System governing research for the Toronto Infectious Bacterial Disease Network (TIBDN) under the study title “Surveillance for Meningitis/Invasive Bacterial Disease and Related Studies”. (c) This Agreement shall not be amended, modified, varied or supplemented except in writing signed by each of the parties. (d) No failure or delay on the part of any party hereto to exercise any right or remedy under this Agreement (and any Implementing Form) shall be construed or operate as a waiver thereof. (e) The parties hereto are independent contractors. Nothing contained herein shall be deemed or construed to create between or among the parties hereto a partnership or joint venture or employment or principal-agent relationship. No party shall have the authority to act on behalf of any other party or to bind another party in any manner. (f) Each party to this Agreement assumes responsibility for its own obligations under this Agreement. (g) No party shall use, or authorize others to use, the name, symbols, or marks of another party hereto or its staff for any endorsement purposes without prior written approval from the party whose name, symbols or marks are to be used. (h) This Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein. (i) This Agreement and any Joinder Letter Agreement(s) and Implementing Form(s), may be executed electronically and in any number of counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument, or alternatively be executed and exchanged as a single document in electronic format (e.g. “pdf”). Delivery by facsimile or email of any executed counterpart of this Agreement shall be equally as effective as delivery of a manually executed counterpart thereof. The parties agree that the execution of this Agreement by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party hereby waives any right to raise any defence or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically. (j) All terms of this Agreement and any Implementing Form that are stated to survive or which by their nature are intended to survive, shall survive the expiration or earlier termination of this Agreement and such Implementing Form.

[Rest of page left intentionally blank.]

[Signature page(s) follow.]
The parties have executed this Agreement by their duly authorized representative(s):

Institution: University Health Network

Franco Rossetto (Apr 17, 2020)

Name: Franco E. Rossetto, PhD, JD
Title: Senior Director, Research Legal
The parties have executed this Agreement by their duly authorized representative(s):

Institution:

Michael W. Salter, MD PhD FRSC
Chief of Research
The Hospital for Sick Children
Professor of Physiology
University of Toronto

Name: ____________________________
Title: ____________________________
April 17, 2020
The parties have executed this Agreement by their duly authorized representative(s):

Institution: Sinai Health System

Name: Dr. Jim Woodgett
Title: Director, Lunenfeld-Tanenbaum Research Institute
The parties have executed this Agreement by their duly authorized representative(s):

Institution: The Governing Council of the University of Toronto

Name: Vivek Goel
Title: Vice President, Research and Innovation, and Strategic Initiatives
The parties have executed this Agreement by their duly authorized representative(s):

BAYCREST CENTRE FOR GERIATRIC CARE, FOR ITSELF AND AS AGENT FOR BAYCREST HOSPITAL

Dr. Allison Sekuler
Vice President, Research

B. Mackie

Brian Mackie
Vice President, Finance & CFO
The parties have executed this Agreement by their duly authorized representative(s):

Institution: **WOMEN'S COLLEGE HOSPITAL**

[Signature]

Name: Greg Chow
Title: Chief Financial Officer
The parties have executed this Agreement by their duly authorized representative(s):

Institution: Unity Health Toronto

Name: Dr. Ori Rotstein
Title: Vice-President, Research and Innovation
The parties have executed this Agreement by their duly authorized representative(s):

Institution: Sunnybrook Research Institute

Kullervo Hynynen
Kullervo Hynynen (Aug 17, 2020)
Name: Dr. Kullervo Hynynen
Title: Vice President, Research and Innovation

Rod Engeland
Rod Engeland (Apr 9, 2020)
Name: Rod Engeland
Title: Executive Director, Research Finance & Operations
The parties have executed this Agreement by their duly authorized representative(s):

CENTRE FOR ADDICTION AND MENTAL HEALTH

[Signature]

Name: Dr. Bruce Pollock
Title: Vice President, Research
The parties have executed this Agreement by their duly authorized representative(s):

Institution: Ontario Institute for Cancer Research

__________________________
Name: Laszlo Radvanyi
Title: President & Scientific Director
The parties have executed this Agreement by their duly authorized representative(s):

Institution: Holland Bloorview Kids Rehabilitation Hospital, Bloorview Research Institute

[Signature]

Name: Tom Chau
Title: VP Research, Bloorview Research Institute
SCHEDULE “A”
Form of “Implementing Form”

Date: XXX

From: [PROVIDING PARTY’S TECHNOLOGY TRANSFER OFFICE (or equivalent)]
CC: [PROVIDING PARTY’S INVESTIGATOR(S)]
[INSERT CONTACT INFORMATION/ADDRESS (as required)]

To: [RECEIVING PARTY’S TECHNOLOGY TRANSFER OFFICE (or equivalent)]
CC: [RECEIVING PARTY’S INVESTIGATOR(S)]
[INSERT CONTACT INFORMATION/ADDRESS (as required)]

This Implementing Form documents the agreement between the Providing Party and the Receiving Party in respect of a Data/Sample(s) transfer pursuant to the Master Data & Biological Sample Transfer Agreement (the “Agreement”; initially dated April 17/2020).

This Implementing Form incorporates by reference the terms, conditions and provisions of the Agreement (the “Terms/Conditions”) in respect of the transfer of the Data/Sample(s), as such Terms/Conditions are further supplemented, amended or overridden as noted below. In the event of a conflict between this Implementing Form and the Agreement, the terms, conditions and provisions of this Implementing Form shall prevail.

All term(s) used but not defined herein shall have the respective meaning(s) set forth in the Agreement.

No Data/Sample(s) will be transferred pursuant to the Agreement absent the execution of this Implementing Form.

The parties to this Implementing Form shall be solely responsible for the implementation, administration (including recordkeeping), supervision and performance of any Study and Research Project described herein, and for clarity shall be further solely responsible for maintaining adequate record(s) of all such executed Implementing Form(s).

This Implementing Form may be executed electronically and in any number of counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument, or alternatively be executed and exchanged as a single document in electronic format (e.g. “pdf”). The parties agree that the execution of this Agreement by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party hereby waives any right to raise any defence or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically.

Study/Research Project Title: [INSERT INFORMATION]

REB Study Approval Information (as required): [INSERT INFORMATION]

“Data/Sample(s)” description: [INSERT INFORMATION]

Permitted use of Data/Sample(s): [e.g. description of use, and/or parties may choose to attach Study protocol or Research Project protocol, etc.]
Other terms, conditions and provisions: [e.g. conditions contained in the participants’ informed consents (as applicable), conditions imposed by Party’s REB, third party IP obligations, unique terms/provisions for the transfer and use of these particular Data/Sample(s), modification of Agreement terms/provisions, etc.]

The parties have executed this Implementing Form by their duly authorized representatives:

[INSERT Institutional Signature Blocks]

ACKNOWLEDGED by:

Providing Party Investigator

________________________
Name:

Receiving Party Investigator

________________________
Name:
SCHEDULE “B”
Form of “Joinder Letter Agreement”

Joinder Letter Agreement

TO: Agreement Administrator

INSERT DATE
INSERT INSTITUTIONAL ADDRESS (and Contact Information)

RE: Inclusion as a party to a Master Data & Biological Sample Transfer Agreement (the “Agreement”) for the conduct of COVID19-related basic/clinical research activities (the “Research”).

WHEREAS a number of research institutions (collectively referred to as the “Participating Institutions” as that term is defined in the Agreement) are parties to the Agreement (with an effective date of April 17/2020).

In consideration for becoming a Participating Institution, and other good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned hereby declares and agrees as follows:

1. This Joinder Letter Agreement dated and effective AS OF THE DATE FIRST WRITTEN ABOVE is between the above noted institution and the Participating Institutions.

2. INSERT INSTITUTIONAL NAME desires to participate in respect of the Research encompassed by the Agreement. INSERT INSTITUTIONAL NAME represents that it has received and reviewed the Agreement, together with a complete and up-to-date list of all Participating Institutions, and agrees to be bound by the terms and conditions of the Agreement AS OF THE DATE FIRST WRITTEN ABOVE in the same manner as if INSERT INSTITUTIONAL NAME had been an original party thereto.

3. INSERT INSTITUTIONAL NAME shall have all the same rights and entitlements under the Agreement as if INSERT INSTITUTIONAL NAME had been an original party thereto.

4. This Joinder Letter Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein and shall be binding upon INSERT INSTITUTIONAL NAME and their successors, permitted assigns and legal representatives.

EXECUTED by INSERT INSTITUTIONAL NAME through its duly authorized representative(s).

Per: ______________________________________
Name/Title: ________________________________
SCHEDULE “C”
Participating Institutions (as updated)

University Health Network
Franco E. Rossetto, PhD, JD
Senior Director, Research Legal
101 College Street, Suite 150
Toronto, ON M5G 1L7
Phone: 416-581-7813
Franco.rossetto@uhnresearch.ca

The Hospital for Sick Children
Christopher R. Viney
General Counsel
555 University Ave
Toronto, ON M5G 1X8
Phone: 416.813.7811
Fax: 416.813.5968
chris.viney@sickkids.ca

Sinai Health System
Office of Technology Transfer
600 University, Suite 843
Toronto, Ontario M5G 1X5
Attn: Dr. Darlene Homonko, Director
Email: homonko@lunenfeld.ca

The Governing Council of the University of Toronto
Innovations & Partnerships Office
100 College Street, Rm. 413
Toronto, ON M5G 1L5
Innovations.partnerships@utoronto.ca

Baycrest Centre for Geriatric Care
Dr. Allison Sekuler
Vice President, Research
Baycrest Centre for Geriatric Care
3560 Bathurst Street
Toronto, Ontario M6A 2E1
E-mail: vpr@research.baycrest.org
cc. Jean Lazarus
Director, Research Operations
Baycrest Centre for Geriatric Care
3560 Bathurst Street
Toronto, Ontario, M6A 2E1
E-mail: jlazarus@baycrest.org

Women’s College Hospital
76 Grenville Street, Toronto, ON M5S 1B2
Contact Information for Contract Administration:
Zohar Zolotnitsky
Research Contracts Specialist
Women’s College Hospital
76 Grenville Street, Room 6325
Toronto, ON M5S 1B2
Tel: (416) 323-6400 ext. 2720
Email: researchcontracts@wchospital.ca

Unity Health Toronto
Dalton Charters
Senior Director, Research Operations
Dalton.Charters@unityhealth.to
Fax# (416) 864-6043

Sunnybrook Research Institute
2075 Bayview Avenue, Toronto, ON M4N 3M5
Attention: Office of the President and CEO, Room C-104

CAMH
Centre for Addiction and Mental Health
33 Russell Street
Toronto, ON M5S 2S1
Attn: Dr. Bruce Pollock
Email: Bruce.Pollock@camh.ca

With a copy to:
E-mail: researchcontracts@camh.ca

Ontario Institute for Cancer Research
Laszlo G. Radvanyi, Ph.D.
President and Scientific Director
Holland Bloorview Kids Rehabilitation Hospital
Grants, Contracts & Awards Officer
Bloorview Research Institute
150 Kilgour Road
Toronto, ON M4G 1R8
T: (416) 425-6220 ext. 3242 or (416) 436-5716
F: (416) 425-1634
E: meghann.proulx@hollandbloorview.ca